Overview

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
0
Participant gender:
All
Summary
This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with follow-up until 2017.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Astellas Pharma Europe B.V.
Collaborator:
World Health Information Science Consultants, LLC
Treatments:
Amphotericin B
Anidulafungin
Antifungal Agents
Caspofungin
Clotrimazole
Echinocandins
Fluconazole
Itraconazole
Micafungin
Miconazole
Voriconazole
Criteria
Inclusion Criteria:

- hospitalized and treated with parenteral antifungal medication

- first time treatment of the patient with parenteral antifungal in the medical center
was anytime from 2005 through 2012

Exclusion Criteria:

- prior diagnosis of hepatocellular carcinoma

- had received parenteral antifungal therapy during the 6 months prior to index
hospitalization